Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Lancet Neurol

Retrieve available abstracts of 142 articles:
HTML format

Single Articles

    February 2024
  1. MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al
    Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
    Lancet Neurol. 2024;23:157-167.
    PubMed     Abstract available

    Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke.
    Lancet Neurol. 2024;23:125-127.

  3. SIMUNI T, Chahine LM, Poston K, Brumm M, et al
    A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research.
    Lancet Neurol. 2024;23:178-190.
    PubMed     Abstract available

  4. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available

    January 2024
  5. SHARMA M, Molina CA, Toyoda K, Bereczki D, et al
    Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Lancet Neurol. 2024;23:46-59.
    PubMed     Abstract available

    Anticoagulants to prevent recurrent non-cardioembolic stroke.
    Lancet Neurol. 2024;23:3-5.

    Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage.
    Lancet Neurol. 2024;23:12-13.

    December 2023
  8. BRIGO F
    The (hi)story of stroke.
    Lancet Neurol. 2023;22:1110.

    Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.
    Lancet Neurol. 2023;22:1091-1092.

    November 2023
  10. KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al
    Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial.
    Lancet Neurol. 2023;22:991-1004.
    PubMed     Abstract available

  11. RUBIANO AM, Lee K
    Traumatic brain injury research: homogenising heterogeneity.
    Lancet Neurol. 2023;22:973-975.

  12. ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al
    Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
    Lancet Neurol. 2023;22:1061-1074.
    PubMed     Abstract available

    October 2023
  13. MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al
    Digital mobility measures to predict Parkinson's disease.
    Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376.

  14. SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al
    Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326.
    PubMed     Abstract available

  15. AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al
    Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315.
    PubMed     Abstract available

  16. KAMEL H
    Reassessing the implications of atrial fibrillation detected after stroke.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406.

  17. BRUSCA SB, Albert MA
    Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386.

    Policy priorities for preventing stroke-related mortality and disability worldwide.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387.

  19. FEIGIN VL, Owolabi MO
    Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.
    Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277.

  20. MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al
    Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
    Lancet Neurol. 2023;22:946-958.
    PubMed     Abstract available

  21. IZZY S, Grashow R, Radmanesh F, Chen P, et al
    Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention.
    Lancet Neurol. 2023;22:959-970.
    PubMed     Abstract available

    September 2023
  22. HUGGER SS, Do TP, Ashina H, Goicochea MT, et al
    Migraine in older adults.
    Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206.
    PubMed     Abstract available

  23. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
    The assessment of dysphagia after stroke: state of the art and future directions.
    Lancet Neurol. 2023;22:858-870.
    PubMed     Abstract available

  24. FENG W
    Diagnosis of post-stroke dysphagia: towards better treatment.
    Lancet Neurol. 2023;22:778-779.

  25. OSPEL JM, Goyal M
    Prehospital triage in acute stroke: which questions to ask?
    Lancet Neurol. 2023;22:771-772.

  26. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
    Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
    Lancet Neurol. 2023;22:812-825.
    PubMed     Abstract available

  27. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
    Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
    Lancet Neurol. 2023;22:800-811.
    PubMed     Abstract available

    August 2023
  28. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
    The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
    Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
    PubMed     Abstract available

  29. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
    Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
    PubMed     Abstract available

  30. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
    Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
    Lancet Neurol. 2023;22:750-768.
    PubMed     Abstract available

  31. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
    Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
    Lancet Neurol. 2023;22:712-722.
    PubMed     Abstract available

  32. MAYNARD G, Kannan R, Liu J, Wang W, et al
    Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
    Lancet Neurol. 2023;22:672-684.
    PubMed     Abstract available

  33. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
    Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2023;22:661-671.
    PubMed     Abstract available

    July 2023
  34. ENGLISH C, Ramage E
    Secondary stroke prevention: more questions than answers.
    Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.

  35. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
    The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
    PubMed     Abstract available

  36. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Lancet Neurol. 2023;22:557-567.
    PubMed     Abstract available

  37. FRISONI GB, van der Flier W
    STRIVEing to describe small vessel disease.
    Lancet Neurol. 2023;22:548-549.

  38. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Lancet Neurol. 2023;22:578-590.
    PubMed     Abstract available

  39. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
    Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Lancet Neurol. 2023;22:568-577.
    PubMed     Abstract available

  40. MEISEL A
    Are CAR T cells the answer to myasthenia gravis therapy?
    Lancet Neurol. 2023;22:545-546.

    June 2023
    Stroke care quality-why recognition matters.
    Lancet Neurol. 2023;22:471.

  42. HAYWARD KS, Bernhardt J
    Aspiring to restore arm and hand function after stroke.
    Lancet Neurol. 2023;22:464-465.

    May 2023
  43. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
    Neuroimaging standards for research into small vessel disease-advances since 2013.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
    PubMed     Abstract available

  44. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
    Progression of cerebral amyloid angiopathy: a pathophysiological framework.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
    PubMed     Abstract available

  45. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Neurol. 2023;22:395-406.
    PubMed     Abstract available

  46. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Lancet Neurol. 2023;22:383-394.
    PubMed     Abstract available

  47. KASKI D, Koohi N, Haider S, Chandratheva A, et al
    The hyperacute vestibular syndrome: ear or brain?
    Lancet Neurol. 2023;22:377-378.

    April 2023
  48. WU S, Anderson CS
    Antiplatelets for secondary stroke prevention in China.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.

  49. PAN Y, Meng X, Yuan B, Johnston SC, et al
    Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
    PubMed     Abstract available

  50. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
    Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lancet Neurol. 2023;22:320-329.
    PubMed     Abstract available

  51. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
    Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
    Lancet Neurol. 2023;22:312-319.
    PubMed     Abstract available

  52. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
    The International Stroke Recovery and Rehabilitation Alliance.
    Lancet Neurol. 2023;22:295-296.

    The quest for optimal blood pressure management after stroke.
    Lancet Neurol. 2023;22:285-286.

  54. FEIGIN VL, Brainin M, Martins SCO
    The polypill from a public-health perspective.
    Lancet Neurol. 2023;22:294-295.

    March 2023
  55. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
    Thrombolysis for acute ischaemic stroke: current status and future perspectives.
    Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
    PubMed     Abstract available

  56. REIFF T, Eckstein HH, Mansmann U, Hacke W, et al
    Treatment of asymptomatic carotid stenosis in SPACE-2 - Authors' reply.
    Lancet Neurol. 2023;22:198-199.

    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197-198.

  58. GOEL A, Soteriou I, Normando E
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197.

  59. THORNTON CA, Moxley RT 3rd, Eichinger K, Heatwole C, et al
    Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
    Lancet Neurol. 2023;22:218-228.
    PubMed     Abstract available

  60. LIPTON RB, Croop R, Stock DA, Madonia J, et al
    Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
    Lancet Neurol. 2023;22:209-217.
    PubMed     Abstract available

    February 2023
  61. ALEMSEGED F, Nguyen TN, Coutts SB, Cordonnier C, et al
    Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice.
    Lancet Neurol. 2023 Feb 10:S1474-4422(22)00483.
    PubMed     Abstract available

  62. MONICHE F, Cabezas-Rodriguez JA, Valverde R, Escudero-Martinez I, et al
    Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Lancet Neurol. 2023;22:137-146.
    PubMed     Abstract available

    Intra-arterial bone marrow mononuclear cells for stroke.
    Lancet Neurol. 2023;22:105-106.

    January 2023
  64. GOYAL M, Singh N, Ospel J
    Clinical trials in stroke in 2022: new answers and questions.
    Lancet Neurol. 2023;22:9-10.

  65. JENSEN M, Suling A, Metzner A, Schnabel RB, et al
    Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial.
    Lancet Neurol. 2023;22:45-54.
    PubMed     Abstract available

  66. DROUIN E, Pasquini M, Hautecoeur P
    The advent of stroke units.
    Lancet Neurol. 2023;22:31.

  67. CALVERT P, Gupta D, Lip GYH
    Early atrial fibrillation rhythm control after stroke.
    Lancet Neurol. 2023;22:3-4.

  68. PENSATO U, Romoli M, Lazzarin SM, Marcheselli S, et al
    The shortage of thrombolytics for stroke: a call for action.
    Lancet Neurol. 2023;22:28.

    December 2022
  69. ROALDSEN MB, Eltoft A, Wilsgaard T, Christensen H, et al
    Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00484.
    PubMed     Abstract available

  70. MUIR KW
    Treatment of wake-up stroke: stick or TWIST?
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00515.

    Tackling the burden of stroke with primordial prevention.
    Lancet Neurol. 2022;21:1061.

  72. SOILEAU MJ, Aldred J, Budur K, Fisseha N, et al
    Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:1099-1109.
    PubMed     Abstract available

    November 2022
  73. KUHLMANN T, Moccia M, Coetzee T, Cohen JA, et al
    Multiple sclerosis progression: time for a new mechanism-driven framework.
    Lancet Neurol. 2022 Nov 18:S1474-4422(22)00289.
    PubMed     Abstract available

  74. CHURILOV L, Bivard A, Parsons MW
    Tenecteplase versus alteplase for early treatment of ischaemic stroke - Authors' reply.
    Lancet Neurol. 2022;21:959.

    Tenecteplase versus alteplase for early treatment of ischaemic stroke.
    Lancet Neurol. 2022;21:959.

    October 2022
  76. HOU C, Lan J, Lin Y, Song H, et al
    Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00335.
    PubMed     Abstract available

  77. GANESH A, Smith EE, Hill MD
    Remote ischaemic conditioning for stroke prevention.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00438.

  78. HOBEANU C, Lavallee PC, Charles H, Labreuche J, et al
    Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.
    Lancet Neurol. 2022;21:889-898.
    PubMed     Abstract available

  79. REIFF T, Eckstein HH, Mansmann U, Jansen O, et al
    Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial.
    Lancet Neurol. 2022;21:877-888.
    PubMed     Abstract available

  80. BURTON A
    Valeria Caso: because women have strokes too.
    Lancet Neurol. 2022;21:873.

    Long-term disability after transient ischaemic attack or minor stroke.
    Lancet Neurol. 2022;21:859-860.

    September 2022
  82. PETER-DEREX L, Philippeau F, Garnier P, Andre-Obadia N, et al
    Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:781-791.
    PubMed     Abstract available

  83. SYKES L, Akpalu A, Gordon C, Cullen L, et al
    Developing stroke care services in west Africa.
    Lancet Neurol. 2022;21:778-779.

  84. VAN DEN BERG SA, Uniken Venema SM, Reinink H, Hofmeijer J, et al
    Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00333.
    PubMed     Abstract available

  85. SANDSET EC, Walter S, Song L
    The challenges of large-scale prehospital stroke trials.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00356.

    August 2022
  86. BRAININ M, Grisold W, Hankey GJ, Norrving B, et al
    Time to revise primary prevention guidelines for stroke and cardiovascular disease.
    Lancet Neurol. 2022;21:686-687.

    June 2022
  87. BAAK LM, Wagenaar N, van der Aa NE, Groenendaal F, et al
    Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
    Lancet Neurol. 2022;21:528-536.
    PubMed     Abstract available

  88. GONZALEZ F, Ferriero DM
    Stem cells for perinatal stroke.
    Lancet Neurol. 2022;21:497-499.

    No area of stroke research should be left behind.
    Lancet Neurol. 2022;21:495.

    May 2022
    20 years of improvement in stroke care: the rewards from finally funding more research.
    Lancet Neurol. 2022;21:402-404.

    April 2022
  91. BIVARD A, Zhao H, Churilov L, Campbell BCV, et al
    Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00171.
    PubMed     Abstract available

  92. KVISTAD CE, Naess H, Helleberg BH, Idicula T, et al
    Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00124.
    PubMed     Abstract available

    Tenecteplase for acute stroke: the thrombolysis puzzle.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00172.

  94. HILL G, Regan S, Francis R
    Research priorities to improve stroke outcomes.
    Lancet Neurol. 2022;21:312-313.

    March 2022
  95. BONATI LH, Jansen O, de Borst GJ, Brown MM, et al
    Management of atherosclerotic extracranial carotid artery stenosis.
    Lancet Neurol. 2022;21:273-283.
    PubMed     Abstract available

    February 2022
  96. ZHAO J, Yuan F, Song C, Yin R, et al
    Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00010.
    PubMed     Abstract available

    Nutrition in acute stroke management: food for thought.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00078.

  98. GUTIERREZ J, Turan TN, Hoh BL, Chimowitz MI, et al
    Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.
    Lancet Neurol. 2022 Feb 7. pii: S1474-4422(21)00376.
    PubMed     Abstract available

    Jeyaraj Pandian: passionate about improving stroke care in India.
    Lancet Neurol. 2022;21:120.

    January 2022
  100. BAILLIEUL S, Dekkers M, Brill AK, Schmidt MH, et al
    Sleep apnoea and ischaemic stroke: current knowledge and future directions.
    Lancet Neurol. 2022;21:78-88.
    PubMed     Abstract available

  101. PUY L, Cordonnier C
    Stroke research in 2021: insights into the reorganisation of stroke care.
    Lancet Neurol. 2022;21:2-3.

    December 2021
  102. FEIGIN VL
    Primary stroke prevention: useful thresholds?
    Lancet Neurol. 2021 Dec 16. pii: S1474-4422(21)00458.

    November 2021
  103. SCHREUDER FHBM, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, et al
    Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
    Lancet Neurol. 2021;20:907-916.
    PubMed     Abstract available

    September 2021
  104. PANDIAN JD, Sebastian IA
    Integrated approach to stroke burden: are we doing enough?
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00287.

  105. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00252.
    PubMed     Abstract available

  106. CASO V, Mosconi MG
    Lessons to be learned in intracerebral haemorrhage research.
    Lancet Neurol. 2021 Sep 2. pii: S1474-4422(21)00296.

  107. HOWARD DPJ, Rothwell PM
    Asymptomatic carotid stenosis and stroke risk - Authors' reply.
    Lancet Neurol. 2021;20:699.

  108. ABBOTT A
    Asymptomatic carotid stenosis and stroke risk.
    Lancet Neurol. 2021;20:698-699.

  109. ROTHWELL PM, Buchan AM
    A new thrombolytic drug for acute ischaemic stroke.
    Lancet Neurol. 2021;20:687-689.

  110. GUSEV EI, Martynov MY, Nikonov AA, Shamalov NA, et al
    Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Lancet Neurol. 2021;20:721-728.
    PubMed     Abstract available

    July 2021
  111. BANDINI F, Vestito L, Filippi L
    Prehospital scales in acute ischaemic stroke management.
    Lancet Neurol. 2021;20:504.

  112. DUVEKOT MHC, Venema E, Kerkhoff H, Dippel DWJ, et al
    Prehospital scales in acute ischaemic stroke management - Authors' reply.
    Lancet Neurol. 2021;20:504-505.

    June 2021
  113. LI L, Poon MTC, Samarasekera NE, Perry LA, et al
    Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.
    Lancet Neurol. 2021;20:437-447.
    PubMed     Abstract available

  114. HAEUSLER KG, Kirchhof P, Kunze C, Tutuncu S, et al
    Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study.
    Lancet Neurol. 2021;20:426-436.
    PubMed     Abstract available

  115. CHENG X, Dong Q
    Towards individualised secondary prevention after intracerebral haemorrhage.
    Lancet Neurol. 2021;20:411-413.

  116. WASSERLAUF J, Volgman AS
    Monitoring for atrial fibrillation after stroke.
    Lancet Neurol. 2021;20:410-411.

    May 2021
    Michael Moskowitz: solving the puzzle of migraine.
    Lancet Neurol. 2021 May 17. pii: S1474-4422(21)00141.

  118. JORDAN LC, DeBaun MR, Donahue MJ
    Advances in neuroimaging to improve care in sickle cell disease.
    Lancet Neurol. 2021;20:398-408.
    PubMed     Abstract available

  119. HACHINSKI V, Avan A, Gilliland J, Oveisgharan S, et al
    A new definition of brain health.
    Lancet Neurol. 2021;20:335-336.

    April 2021
  120. WEAVER NA, Kuijf HJ, Aben HP, Abrigo J, et al
    Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00060.
    PubMed     Abstract available

  121. PANTONI L, Salvadori E
    Location of infarcts and post-stroke cognitive impairment.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00107.

  122. BEST JG, Ambler G, Wilson D, Lee KJ, et al
    Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from
    Lancet Neurol. 2021;20:294-303.
    PubMed     Abstract available

    Cerebral microbleeds and prediction of intracranial haemorrhage.
    Lancet Neurol. 2021;20:252-254.

  124. ZIAI WC, Al-Kawaz M
    Blood pressure management after endovascular therapy.
    Lancet Neurol. 2021;20:248-249.

  125. LAUMANN TO, Ortega M, Hoyt CR, Seider NA, et al
    Brain network reorganisation in an adolescent after bilateral perinatal strokes.
    Lancet Neurol. 2021;20:255-256.

    March 2021
  126. SCHMIDT R, Hofer E
    Identifying novel genetic risk loci for lacunar stroke.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00099.

  127. TRAYLOR M, Persyn E, Tomppo L, Klasson S, et al
    Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00031.
    PubMed     Abstract available

  128. ENGELTER ST, Traenka C, Gensicke H, Schaedelin SA, et al
    Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.
    Lancet Neurol. 2021 Mar 22. pii: S1474-4422(21)00044.
    PubMed     Abstract available

  129. HOWARD DPJ, Gaziano L, Rothwell PM
    Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.
    Lancet Neurol. 2021;20:193-202.
    PubMed     Abstract available

  130. VAN DIJCK JTJM, Kompanje EJO, Nederkoorn PJ, Peul WC, et al
    Advanced consent for acute stroke trials - Authors' reply.
    Lancet Neurol. 2021;20:170-171.

  131. SHAMY M, Dewar B, Niznick N, Nicholls S, et al
    Advanced consent for acute stroke trials.
    Lancet Neurol. 2021;20:170.

  132. SPENCE JD
    Treatment of asymptomatic carotid stenosis.
    Lancet Neurol. 2021;20:163-165.

    February 2021
  133. MAZIGHI M, Richard S, Lapergue B, Sibon I, et al
    Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2021 Feb 26. pii: S1474-4422(20)30483.
    PubMed     Abstract available

    January 2021
  134. DUVEKOT MHC, Venema E, Rozeman AD, Moudrous W, et al
    Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30439.
    PubMed     Abstract available

  135. GOYAL M, Marko M
    Optimising prehospital stroke triage in a changing landscape.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30488.

  136. TSIVGOULIS G, Katsanos AH
    Important advances in stroke research in 2020.
    Lancet Neurol. 2021;20:2-3.

    December 2020
  137. WU S, Anderson CS
    Healthy eating for secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30450.

  138. ENGLISH C, MacDonald-Wicks L, Patterson A, Attia J, et al
    The role of diet in secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30433.
    PubMed     Abstract available

  139. SILBERGLEIT R, Dickert NW
    Context and principles must drive alternatives to consent in emergency research.
    Lancet Neurol. 2020;19:968-969.

    November 2020
    A unified European action plan on stroke.
    Lancet Neurol. 2020 Nov 6. pii: S1474-4422(20)30409.

    October 2020
  141. MERETOJA A, Yassi N, Wu TY, Churilov L, et al
    Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2020 Oct 28. pii: S1474-4422(20)30369.
    PubMed     Abstract available

  142. KOMPANJE EJO, van Dijck JTJM, Chalos V, van den Berg SA, et al
    Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke.
    Lancet Neurol. 2020 Oct 21. pii: S1474-4422(20)30276.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Stroke is free of charge.